Verve Therapeutics IncNASDAQ:VERV
- LAST PRICE5.2300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots5.2000/ 1
- Ask / Lots5.4000/ 1
- Open / Previous Close0.0000 / 5.2300
- Day Range---
- 52 Week Range
- Volume2
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VERV |
|---|---|---|
| 09:32 ET | 10849 | 5.25 |
| 09:34 ET | 1254 | 5.25 |
| 09:36 ET | 800 | 5.27 |
| 09:38 ET | 2600 | 5.25 |
| 09:39 ET | 9247 | 5.29 |
| 09:41 ET | 100 | 5.27 |
| 09:43 ET | 716 | 5.26 |
| 09:45 ET | 996 | 5.26 |
| 09:48 ET | 24936 | 5.25 |
| 09:50 ET | 13973 | 5.25 |
| 09:52 ET | 2309 | 5.25 |
| 09:54 ET | 2780 | 5.27 |
| 09:56 ET | 4750 | 5.23 |
| 09:57 ET | 3847 | 5.17 |
| 09:59 ET | 1442 | 5.16 |
| 10:01 ET | 19700 | 5.185 |
| 10:03 ET | 8690 | 5.22 |
| 10:06 ET | 785 | 5.245 |
| 10:08 ET | 1600 | 5.255 |
| 10:10 ET | 2905 | 5.25 |
| 10:12 ET | 3617 | 5.25 |
| 10:14 ET | 1100 | 5.25 |
| 10:15 ET | 633 | 5.26 |
| 10:17 ET | 789 | 5.26 |
| 10:19 ET | 314 | 5.25 |
| 10:21 ET | 2535 | 5.28 |
| 10:24 ET | 2481 | 5.31 |
| 10:26 ET | 300 | 5.31 |
| 10:28 ET | 553 | 5.27 |
| 10:30 ET | 1000 | 5.27 |
| 10:32 ET | 3233 | 5.26 |
| 10:35 ET | 13241 | 5.25 |
| 10:37 ET | 1542 | 5.26 |
| 10:39 ET | 100 | 5.265 |
| 10:42 ET | 2441 | 5.265 |
| 10:44 ET | 799 | 5.26 |
| 10:46 ET | 100 | 5.25 |
| 10:48 ET | 724 | 5.25 |
| 10:50 ET | 1000 | 5.27 |
| 10:51 ET | 1300 | 5.27 |
| 10:53 ET | 1721 | 5.28 |
| 10:55 ET | 766 | 5.2887 |
| 10:57 ET | 530 | 5.299 |
| 11:00 ET | 200 | 5.29 |
| 11:02 ET | 500 | 5.29 |
| 11:04 ET | 4125 | 5.295 |
| 11:06 ET | 1782 | 5.29 |
| 11:08 ET | 1500 | 5.3 |
| 11:09 ET | 100 | 5.295 |
| 11:11 ET | 400 | 5.3 |
| 11:13 ET | 3694 | 5.3 |
| 11:15 ET | 300 | 5.29 |
| 11:18 ET | 100 | 5.29 |
| 11:20 ET | 704 | 5.275 |
| 11:22 ET | 641 | 5.26 |
| 11:24 ET | 100 | 5.25 |
| 11:26 ET | 100 | 5.26 |
| 11:27 ET | 200 | 5.26 |
| 11:29 ET | 1897 | 5.25 |
| 11:31 ET | 600 | 5.25 |
| 11:33 ET | 700 | 5.25 |
| 11:36 ET | 2185 | 5.2599 |
| 11:38 ET | 1500 | 5.255 |
| 11:40 ET | 1842 | 5.255 |
| 11:42 ET | 300 | 5.255 |
| 11:44 ET | 300 | 5.255 |
| 11:45 ET | 2205 | 5.26 |
| 11:47 ET | 2290 | 5.28 |
| 11:49 ET | 100 | 5.285 |
| 11:51 ET | 500 | 5.275 |
| 11:54 ET | 100 | 5.275 |
| 11:56 ET | 533 | 5.28 |
| 11:58 ET | 800 | 5.28 |
| 12:00 ET | 500 | 5.26 |
| 12:05 ET | 2309 | 5.26 |
| 12:07 ET | 200 | 5.25 |
| 12:09 ET | 6574 | 5.255 |
| 12:14 ET | 2690 | 5.255 |
| 12:16 ET | 5629 | 5.25 |
| 12:18 ET | 1511 | 5.2449 |
| 12:20 ET | 1880 | 5.24 |
| 12:21 ET | 900 | 5.25 |
| 12:23 ET | 1600 | 5.245 |
| 12:25 ET | 1260 | 5.245 |
| 12:27 ET | 4195 | 5.255 |
| 12:30 ET | 3544 | 5.265 |
| 12:32 ET | 1592 | 5.245 |
| 12:34 ET | 4391 | 5.25 |
| 12:36 ET | 856 | 5.245 |
| 12:38 ET | 2724 | 5.24 |
| 12:39 ET | 1200 | 5.245 |
| 12:41 ET | 700 | 5.24 |
| 12:43 ET | 500 | 5.245 |
| 12:45 ET | 1688 | 5.255 |
| 12:48 ET | 1548 | 5.265 |
| 12:50 ET | 200 | 5.26 |
| 12:52 ET | 200 | 5.26 |
| 12:54 ET | 1600 | 5.27 |
| 12:56 ET | 517 | 5.27 |
| 12:57 ET | 100 | 5.27 |
| 12:59 ET | 1352 | 5.27 |
| 01:01 ET | 200 | 5.25 |
| 01:03 ET | 300 | 5.26 |
| 01:06 ET | 937 | 5.25 |
| 01:08 ET | 1191 | 5.255 |
| 01:10 ET | 1305 | 5.25 |
| 01:12 ET | 1359 | 5.265 |
| 01:14 ET | 300 | 5.26 |
| 01:15 ET | 5264 | 5.26 |
| 01:17 ET | 1024 | 5.27 |
| 01:21 ET | 1243 | 5.27 |
| 01:24 ET | 440 | 5.2721 |
| 01:26 ET | 1727 | 5.299 |
| 01:28 ET | 100 | 5.2995 |
| 01:32 ET | 500 | 5.29 |
| 01:33 ET | 789 | 5.29 |
| 01:35 ET | 300 | 5.29 |
| 01:37 ET | 800 | 5.29 |
| 01:39 ET | 1200 | 5.3 |
| 01:42 ET | 1826 | 5.295 |
| 01:44 ET | 1200 | 5.29 |
| 01:46 ET | 6622 | 5.3 |
| 01:48 ET | 1228 | 5.285 |
| 01:50 ET | 400 | 5.2825 |
| 01:51 ET | 3851 | 5.29 |
| 01:53 ET | 782 | 5.295 |
| 01:55 ET | 1100 | 5.295 |
| 01:57 ET | 600 | 5.29 |
| 02:00 ET | 4773 | 5.285 |
| 02:02 ET | 200 | 5.27 |
| 02:04 ET | 200 | 5.2701 |
| 02:06 ET | 1300 | 5.27 |
| 02:08 ET | 500 | 5.25 |
| 02:09 ET | 200 | 5.25 |
| 02:13 ET | 100 | 5.255 |
| 02:15 ET | 100 | 5.255 |
| 02:18 ET | 2143 | 5.265 |
| 02:20 ET | 800 | 5.255 |
| 02:22 ET | 1200 | 5.25 |
| 02:26 ET | 200 | 5.25 |
| 02:27 ET | 1299 | 5.24 |
| 02:29 ET | 1600 | 5.24 |
| 02:31 ET | 3700 | 5.245 |
| 02:33 ET | 3367 | 5.2699 |
| 02:36 ET | 600 | 5.265 |
| 02:38 ET | 200 | 5.265 |
| 02:40 ET | 2731 | 5.25 |
| 02:42 ET | 2000 | 5.25 |
| 02:44 ET | 300 | 5.2425 |
| 02:45 ET | 3666 | 5.225 |
| 02:47 ET | 3269 | 5.23 |
| 02:49 ET | 811 | 5.235 |
| 02:51 ET | 600 | 5.23 |
| 02:54 ET | 600 | 5.235 |
| 02:56 ET | 5318 | 5.235 |
| 02:58 ET | 700 | 5.23 |
| 03:00 ET | 400 | 5.23 |
| 03:02 ET | 4003 | 5.21 |
| 03:03 ET | 4400 | 5.21 |
| 03:05 ET | 600 | 5.215 |
| 03:07 ET | 300 | 5.22 |
| 03:09 ET | 2413 | 5.2 |
| 03:12 ET | 4152 | 5.21 |
| 03:14 ET | 9477 | 5.22 |
| 03:16 ET | 1484 | 5.22 |
| 03:18 ET | 1100 | 5.225 |
| 03:20 ET | 1200 | 5.225 |
| 03:21 ET | 4338 | 5.225 |
| 03:23 ET | 5134 | 5.245 |
| 03:25 ET | 3313 | 5.26 |
| 03:27 ET | 3063 | 5.25 |
| 03:30 ET | 3400 | 5.24 |
| 03:32 ET | 1773 | 5.255 |
| 03:34 ET | 2511 | 5.25 |
| 03:36 ET | 6040 | 5.25 |
| 03:38 ET | 880 | 5.26 |
| 03:39 ET | 832 | 5.255 |
| 03:41 ET | 5071 | 5.26 |
| 03:43 ET | 1474 | 5.2501 |
| 03:45 ET | 7622 | 5.245 |
| 03:48 ET | 6447 | 5.24 |
| 03:50 ET | 3335 | 5.25 |
| 03:52 ET | 10934 | 5.24 |
| 03:54 ET | 4732 | 5.25 |
| 03:56 ET | 24138 | 5.25 |
| 03:57 ET | 38881 | 5.25 |
| 03:59 ET | 62322 | 5.23 |
Yesterday
Jun 24, 2024
Jun 23, 2024
Jun 22, 2024
Jun 21, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Verve Therapeutics Inc | 439.1M | -1.8x | --- |
Taysha Gene Therapies Inc | 461.0M | -2.1x | --- |
AC Immune SA | 397.8M | -5.9x | --- |
Applied Therapeutics Inc | 507.3M | -2.3x | --- |
Nkarta Inc | 432.0M | -2.6x | --- |
Larimar Therapeutics Inc | 448.8M | -7.3x | --- |
Company Information
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH). VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies.
Contact Information
- Headquarters
- 201 Brookline Avenue, Suite 601BOSTON, MA, United States 02215
- Phone
- 978-501-3026
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Burt Adelman
- President, Chief Operating Officer, General Counsel
- Andrew Ashe
- Chief Executive Officer, Director
- Sekar Kathiresan
- Chief Financial Officer
- Allison Dorval
- Chief Administrative Officer
- Joan Nickerson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $439.1M |
|---|---|
Revenue (TTM) | $16.0M |
Shares Outstanding | 84.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.87 |
Book Value | $7.31 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | 27.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,381.45% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
